We are currently in the process of setting up a randomised control trial, BEST3, to evaluate if the Cytosponge-TFF3 test leads to an increase in the number of patients diagnosed with BE in primary care, and to gain an in-depth understanding of the associated health economics. The gene discussed is TFF3; the disease is Barrett esophagus.